AgomAb Therapeutics NV (AGMB)
NASDAQ: AGMB · Real-Time Price · USD
11.52
+0.58 (5.30%)
At close: May 22, 2026, 4:00 PM EDT
11.50
-0.02 (-0.17%)
After-hours: May 22, 2026, 4:10 PM EDT
AgomAb Therapeutics NV Stock Forecast
Stock Price Forecast
According to 3 analysts polled by S&P Global, AgomAb Therapeutics NV stock has a consensus rating of "Buy" and an average price target of $37.19. The average 1-year stock price forecast is 222.83% higher than the current stock price, while the lowest is $32.54 (+182.47%) and the highest is $41.84 (+263.19%).
Price Target: $37.19 (+222.83%)
Analyst Consensus: Buy
* Price targets were last updated on Mar 3, 2026.
Analyst Ratings
The average analyst rating for AgomAb Therapeutics NV stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|
| Strong Buy | 0 | 0 | 0 |
| Buy | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 |
| Total | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Leerink Partners | Leerink Partners | Buy Initiates $36 | Buy | Initiates | $36 | +212.50% | Mar 3, 2026 |
| JP Morgan | JP Morgan | Buy Initiates $32 | Buy | Initiates | $32 | +177.78% | Mar 3, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Initiates $28 | Buy | Initiates | $28 | +143.06% | Mar 3, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.55
from -143.22
EPS Next Year
-1.88
from -1.55
Financial currency is EUR. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||||
| Avg | n/a | n/a | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -1.45 | -1.39 | |
| Avg | -1.55 | -1.88 | |
| Low | -1.72 | -2.08 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.